These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 6450431

  • 1. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA, Workman P, Brown JM.
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P.
    Cancer Clin Trials; 1980 Dec; 3(3):237-51. PubMed ID: 7438321
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM.
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [Abstract] [Full Text] [Related]

  • 4. The pharmacokinetics of misonidazole in the dog.
    White RA, Workman P, Freedman LS, Owen LN, Bleehen NM.
    Eur J Cancer (1965); 1979 Oct; 15(10):1233-42. PubMed ID: 520395
    [No Abstract] [Full Text] [Related]

  • 5. Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract.
    Strong JM, Schwade JG, Gangji D, Shoemaker DD, Upton DK.
    Cancer Clin Trials; 1981 Oct; 4(1):41-6. PubMed ID: 7214661
    [No Abstract] [Full Text] [Related]

  • 6. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S, Saunders MI, Dunphy EP, Bennett MH, Des Rochers C, Stratford MR, Minchinton AI, Orchard RA.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
    [Abstract] [Full Text] [Related]

  • 7. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.
    Brown JM, Workman P.
    Radiat Res; 1980 Apr; 82(1):171-90. PubMed ID: 7367588
    [No Abstract] [Full Text] [Related]

  • 8. I.V. misonidazole (NSC 261037). Report of initial clinical experience.
    Schwade JG, Strong JM, Gangji D.
    Cancer Clin Trials; 1981 Apr; 4(1):33-9. PubMed ID: 7214660
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G, Canal P, Mockey E, Vandevoorde E, Laurent F, Soula G.
    J Pharmacol; 1983 Apr; 14(1):67-77. PubMed ID: 6834852
    [Abstract] [Full Text] [Related]

  • 11. [Intensification of cytostatic action by radiosensitizers--a review of the present status of chemosensitization].
    Moldenhauer H, Rose H, Saul G, Wolf G, Kehrberg G.
    Radiobiol Radiother (Berl); 1984 Apr; 25(2):289-95. PubMed ID: 6234615
    [No Abstract] [Full Text] [Related]

  • 12. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 13. [Development of new hypoxic cell radiosensitizer in Japan].
    Mori T, Murayama C.
    Gan No Rinsho; 1988 Oct 01; 34(13):1869-74. PubMed ID: 2974089
    [Abstract] [Full Text] [Related]

  • 14. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
    Minchinton AI, Stratford MR.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1117-20. PubMed ID: 2943710
    [Abstract] [Full Text] [Related]

  • 15. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R, Workman P, Owen L.
    Int J Radiat Oncol Biol Phys; 1982 Jul 01; 8(3-4):473-6. PubMed ID: 7107369
    [Abstract] [Full Text] [Related]

  • 16. The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508.
    Coleman CN, Lee WW, Constine LS, Brown JM.
    Int J Radiat Oncol Biol Phys; 1982 Jul 01; 8(3-4):431-4. PubMed ID: 6213588
    [Abstract] [Full Text] [Related]

  • 17. Radiosensitizers: rationale and potential.
    Brown JM.
    Cancer Treat Rep; 1981 Jul 01; 65 Suppl 2():95-102. PubMed ID: 7346152
    [Abstract] [Full Text] [Related]

  • 18. Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dog.
    White RA, Workman P.
    Cancer Treat Rep; 1980 Jul 01; 64(2-3):360-1. PubMed ID: 7190871
    [No Abstract] [Full Text] [Related]

  • 19. The metabolism and pharmacokinetics of the hypoxic cell radiosensitizer and cytotoxic agent, misonidazole, in C3H mice.
    Chin JB, Rauth AM.
    Radiat Res; 1981 May 01; 86(2):341-57. PubMed ID: 7232696
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799.
    Dische S, Saunders MI, Bennett MH, Dunphy EP, Des Rochers C, Stratford MR, Minchinton AI, Wardman P.
    Br J Radiol; 1986 Sep 01; 59(705):911-7. PubMed ID: 3756388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.